Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Basic and Clinical Physiology and Pharmacology

Editor-in-Chief: Horowitz, Michal

Editorial Board: Das, Kusal K. / Epstein, Yoram / S. Gershon MD, Elliot / Kodesh , Einat / Kohen, Ron / Lichtstein, David / Maloyan, Alina / Mechoulam, Raphael / Roth, Joachim / Schneider, Suzanne / Shohami, Esther / Sohmer, Haim / Yoshikawa, Toshikazu / Tam, Joseph


CiteScore 2016: 1.01

SCImago Journal Rank (SJR) 2016: 0.349
Source Normalized Impact per Paper (SNIP) 2016: 0.495

Online
ISSN
2191-0286
See all formats and pricing
More options …
Volume 26, Issue 2

Issues

Inadvertent use of bevacizumab in pregnant women with diabetes mellitus type 1

Silvio Polizzi / Giovanna Ferrara / Stefano Restaino
  • Department of Gynecology, Institute for Maternal and Child Health IRCCS Burlo Garofolo, University of Trieste, Trieste, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Silvia Rinaldi / Daniele Tognetto
Published Online: 2014-08-05 | DOI: https://doi.org/10.1515/jbcpp-2014-0058

Abstract

Background: The use of vascular endothelial growth factor (VEGF) inhibitors may cause fetal harm and systemic side effects in the mother, so these drugs are contraindicated in pregnancy. We report a case of inadvertent administration of two intravitreal bevacizumab injections in a woman with diabetes mellitus type 1, 5 days before ovulation (±3 days) and during the 5th gestational week, respectively. The patient had a past history of both miscarriage and requirement for cesarean section for preeclampsia.

Methods: Observational case report.

Results: The patient did not have any drug-related adverse event and delivered a healthy full-term infant, reaching all developmental milestones appropriately during infancy.

Conclusions: Intravitreal drug injections did not result in any detectable adverse event in the mother and infant although she had a significant past obstetric history. However, there have been no studies evaluating the effects of bevacizumab in pregnant women and suggesting that intravitreal drug injection in this patient is safe. Until more is known about this, it seems reasonable to avoid treatment with this drug a few weeks before and during pregnancy.

Keywords: bevacizumab; embryo implantation intravitreal injections; preeclampsia; pregnancy; spontaneous miscarriage; VEGF

References

  • 1.

    Tarantola RM, Folk JC, Boldt HC, Mahajan VB. Intravitreal bevacizumab during pregnancy. Retina 2010;30:1405–11.CrossrefGoogle Scholar

  • 2.

    Final labeling text, highlights of prescribing information. U.S.BL 125085/168 Amendment: Bevacizumab – Genentech, Inc. Updated July 2009. South San Francisco, CA: Genentech, Inc. Available at: www.gene.com/gene/products/information/pdf/avastinprescribing.pdf. Accessed on September 10, 2010.

  • 3.

    Almawi WY, Saldanha FL, Mahmood NA, Al-Zaman I, Sater MS, Mustafa FE. Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage. Hum Reprod 2013;28:2628–35.Web of ScienceCrossrefPubMedGoogle Scholar

  • 4.

    Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358–66.Google Scholar

  • 5.

    Gooldman C, Jeyendran RS, Coulam CB. Vascular endothelial growth factor gene polymorphism and implantation failure. Reprod Biomed Online 2008;16:720–3.CrossrefWeb of ScienceGoogle Scholar

  • 6.

    Vuorela P, Carpen O, Tulppala M, Halmesmaki E. VEGF, its receptors and the tie receptors in recurrent miscarriage. Mol Hum Reprod 2000;6:276–82.PubMedCrossrefGoogle Scholar

  • 7.

    Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol 2010;88:e136.Google Scholar

  • 8.

    Gómez. Neovascular membrane and pregnancy. Treatment with bevacizumab. Arch Soc Esp Oftalmol. 2013;88:453–4.Google Scholar

  • 9.

    Granger JP. Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension 2009;54:465–7.CrossrefGoogle Scholar

  • 10.

    Wu Z, Huang J, Sadda S. Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report. Ann Acad Med Singapore 2010;39:143.PubMedGoogle Scholar

  • 11.

    Cross SN, Ratner E, Rutherford TJ, Schwartz PE, Norwitz ER. Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women. Rev Obstet Gynecol 2012;5:2–8.PubMedGoogle Scholar

  • 12.

    Sullivan L, Kelly SP, Glenn A, Williams CP, McKibbin M. Intravitreal bevacizumab injection in unrecognised early pregnancy. Eye (Lond) 2014;28:492–4.Web of ScienceCrossrefGoogle Scholar

  • 13.

    Introini U, Casalino G, Cardani A, Scotti F, Finardi A, Candiani M, et al. Intravitreal bevacizumab for a subfoveal myopic choroidal neovascularization in the first trimester of pregnancy. J Ocul Pharmacol Ther 2012;28:553–5.PubMedCrossrefGoogle Scholar

  • 14.

    Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010;94:1215–8.CrossrefGoogle Scholar

  • 15.

    Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013;97:454–9.CrossrefGoogle Scholar

  • 16.

    Direkvand-Moghadam A, Khosravi A, Sayehmiri K. Predictive factors for preeclampsia in pregnant women: a Receiver Operation Character approach. Arch Med Sci 2013;9:684–9.Web of ScienceCrossrefGoogle Scholar

About the article

Corresponding author: Silvio Polizzi, University Eye Clinic of Trieste – Ophthalmology, Piazza Dell’ Ospitale 1, Trieste 34129, Italy, E-mail:


Received: 2014-05-15

Accepted: 2014-06-24

Published Online: 2014-08-05

Published in Print: 2015-03-01


Citation Information: Journal of Basic and Clinical Physiology and Pharmacology, Volume 26, Issue 2, Pages 161–163, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855, DOI: https://doi.org/10.1515/jbcpp-2014-0058.

Export Citation

©2014 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Zuhair H. Peracha and Philip J. Rosenfeld
Retina, 2016, Volume 36, Number 8, Page 1413
[2]
Silvio Polizzi and Vinit B. Mahajan
Journal of Ocular Pharmacology and Therapeutics, 2015, Volume 31, Number 10, Page 605

Comments (0)

Please log in or register to comment.
Log in